SYMPOSIUM: Clearance of Aβ from the Brain in Alzheimer's Disease: Aβ‐Degrading Enzymes in Alzheimer's Disease

JS Miners, S Baig, J Palmer, LE Palmer… - Brain …, 2008 - Wiley Online Library
In Alzheimer's disease (AD) Aβ accumulates because of imbalance between the production
of Aβ and its removal from the brain. There is increasing evidence that in most sporadic …

[HTML][HTML] Cognitive impact of COVID-19: looking beyond the short term

S Miners, PG Kehoe, S Love - Alzheimer's research & therapy, 2020 - Springer
COVID-19 is primarily a respiratory disease but up to two thirds of hospitalised patients show
evidence of central nervous system (CNS) damage, predominantly ischaemic, in some …

Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier

S Krol, R Macrez, F Docagne, G Defer… - Chemical …, 2013 - ACS Publications
Nanotechnology is an area of growing public interest. Its attractiveness stems from the
promise offered socially and economically by the recent significant advances in …

Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease

D Harold, R Abraham, P Hollingworth, R Sims… - Nature …, 2009 - nature.com
We undertook a two-stage genome-wide association study (GWAS) of Alzheimer's disease
(AD) involving over 16,000 individuals, the most powerful AD GWAS to date. In stage 1 …

Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease

P Hollingworth, D Harold, R Sims, A Gerrish… - Nature …, 2011 - nature.com
We sought to identify new susceptibility loci for Alzheimer's disease through a staged
association study (GERAD+) and by testing suggestive loci reported by the Alzheimer's …

[HTML][HTML] Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease

L Jones, PA Holmans, ML Hamshere, D Harold… - PloS one, 2010 - journals.plos.org
Background Late Onset Alzheimer's disease (LOAD) is the leading cause of dementia.
Recent large genome-wide association studies (GWAS) identified the first strongly …

Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease

PG Kehoe, C Russ, S McIlroy, H Williams, P Holmans… - Nature …, 1999 - nature.com
Cardiff casesa 41 121 36 203 193 (n= 198)(0.21)(0.61)(0.18)(0.51)(0.49) 2.43 Cardiff
controls 12 38 27 62 92(1.4− 4.4)(n= 77)(0.16)(0.49)(0.35)(0.40)(0.60) London casesb 23 88 …

Vascular cognitive impairment neuropathology guidelines (VCING): the contribution of cerebrovascular pathology to cognitive impairment

OA Skrobot, J Attems, M Esiri, T Hortobágyi… - Brain, 2016 - academic.oup.com
There are no generally accepted protocols for post-mortem assessment in cases of
suspected vascular cognitive impairment. Neuropathologists from seven UK centres have …

Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias

NM Davies, PG Kehoe, Y Ben-Shlomo… - Journal of Alzheimer's …, 2011 - content.iospress.com
We investigated whether angiotensin II receptor blockers (ARBs) and angiotensin converting
enzyme inhibitors (ACE-Is) are more strongly associated with Alzheimer's disease (AD) …

Is inhibition of the renin–angiotensin system a new treatment option for Alzheimer's disease?

PG Kehoe, GK Wilcock - The Lancet Neurology, 2007 - thelancet.com
Findings from longitudinal and cross-sectional studies suggest an association between high
blood pressure and dementia, and in turn the use of antihypertensives has been suggested …